| Name | Title | Contact Details |
|---|
Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. Its lead product candidate, omadacycline, is a tetracycline-derived and broad-spectrum antibiotic developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planned in ABSSSI and CABP. It is also developing sarecycline, a tetracycline-derived compound that is in Phase III clinical trials for use in the treatment of acne and rosacea. The company has collaborative research and license agreement with Actavis to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and collaboration agreement with Purdue Pharmaceuticals L.P. to commercialize Intermezzo. Paratek Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
JSJ Pharmaceuticals is a Charleston, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Warner Chilcott is a Rockaway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
FFF Enterprises Inc is a Temecula, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Agadia is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.